• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Ipsen - Articles and news items

EC approves Ipsen’s cabometyx to treat advanced RCC following VEGF-targeted therapy

Industry news / 16 September 2016 / Niamh Louise Marriott,

The European Commission has approved Ibsen’s cabometyx (cabozantinib) 20, 40, 60 mg tablets for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy. Cabometyx (cabozantinib) demonstrated significant clinical benefits across all three efficacy endpoints (OS, PFS, ORR) in a phase 3 study in previously treated patients […]

Ipsen’s kidney cancer drug receives positive CHMP and ‘Promising Innovative Medicine’ status

Industry news / 25 July 2016 / Niamh Louise Marriott, Digital Content Producer

Ipsen announced that CHMP & EMA have provided a positive opinion for Cabometyx for the treatment of advanced renal cell carcinoma (RCC) in adults…

Ipsen announces additional Phase III study results for Dysport

Industry news / 23 October 2015 / Victoria White

The Phase III study evaluated the investigational use of Dysport for the treatment of spastic equinus foot, a condition associated with cerebral palsy in children aged 2-17…

Positive top-line results for Phase 3 telotristat etiprate study

Industry news / 3 August 2015 / Victoria White

A Phase 3 clinical trial met its primary endpoint, showing the benefit of oral telotristat etiprate in treating cancer patients with carcinoid syndrome…